In this regard, it is interesting to note that dual PI3K/mTOR inhibitors, such as NVP-BEZ235, but not various PI3K inhibitors have been reported to downregulate Mcl-1 in various AML cells possibly through suppression of cap-dependent translation [32, 37]. This evidence concerns the gene MCL1 and acute myeloid leukemia.